ALSTON & BIRD LLP for BIOMERIEUX, INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics.
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDER GRAF | — |
| JONATHAN JAGODA | — |
| MICHAEL PARK | — |
| MARK RAYDER | — |
Health Issues HCR
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDER GRAF | — |
| JOYCE E GRESKO | — |
| JONATHAN JAGODA | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MICHAEL PARK | — |
| MARK RAYDER | — |
Medical/Disease Research/Clinical Labs MED
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDER GRAF | — |
| JOYCE E GRESKO | — |
| JONATHAN JAGODA | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MICHAEL PARK | — |
| MARK RAYDER | — |
Medicare/Medicaid MMM
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Support for H.R.3164/S.2426, Ensuring Community Access to Pharmacist Services Act.
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDER GRAF | — |
| JOYCE E GRESKO | — |
| JONATHAN JAGODA | — |
| MICHAEL PARK | — |
| MARK RAYDER | — |
Trade (domestic/foreign) TRD
Discussions regarding tariff proposals.
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Pharmacy PHA
Support for H.R.3164/S.2426, Ensuring Community Access to Pharmacist Services Act.
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
| ROBERT SIGGINS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.